Detecting markers for gastric cancer and developing a diagnostic kit
Gastric Cancer Marker Detection and Its Kit Development
This study is testing a new way to find signs of gastric cancer in blood samples to help doctors diagnose it more accurately and earlier.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 530 (estimated) |
| Sex | All |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Wenzhou, Zhejiang) |
| Trial ID | NCT05010863 on ClinicalTrials.gov |
What this trial studies
This project aims to identify new tumor markers for gastric cancer using protein chips, which will enhance the sensitivity and specificity of diagnosis. It involves recruiting patients with early and advanced gastric cancer, as well as healthy controls, to collect blood samples for analysis. The study will establish a multi-diagnostic model for early screening and produce monoclonal antibodies against identified markers to create a diagnostic kit. The goal is to improve the efficiency and accuracy of gastric cancer detection.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with early or advanced gastric cancer who have not received prior anti-tumor treatments.
Not a fit: Patients with a history of other tumors, autoimmune diseases, or those who have undergone previous anti-tumor treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to earlier and more accurate diagnosis of gastric cancer, improving patient outcomes.
How similar studies have performed: While there have been studies focusing on gastric cancer markers, this approach utilizing protein chips for multi-diagnostic models is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patient 1. Age is greater than or equal to 18 years old (including 18 years old); 2. Patients who are diagnosed with cancer after pathological diagnosis; 3. Can provide enough tissue samples; 4. Have not received anti-tumor treatment in the past; 5. Comply with the principle of informed consent and sign the informed consent form. healthy person: 1. Age is greater than or equal to 18 years old (including 18 years old); 2. No underlying disease; 3. Can provide enough tissue samples; 4. Comply with the principle of informed consent and sign the informed consent form. Exclusion Criteria: 1. The tumor foci cannot be clearly derived from a specific tumor type; 2. Those who have a history of other tumors, autoimmune diseases and allergies; 3. Previously received anti-tumor treatments such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy or Chinese medicines with anti-cancer and anti-tumor effects in the instructions; 4. Participated in any clinical trial within 90 days before the experiment; 5. Received major surgery within 90 days before the experiment; 6. Received bone marrow transplantation 90 days before the experiment; 7. Subjects who may not be able to complete the study due to other reasons or who are determined by the investigator to be unsuitable to participate in this study.
Where this trial is running
Wenzhou, Zhejiang
- No. 109, Xueyuan West Road, Lucheng District, Wenzhou City，Zhejiang provincece — Wenzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Weijian Sun, PhD
- Email: fame198288@126.com
- Phone: 13857772361
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.